BioSpace News Archive

Amneal Pharmaceuticals, Inc. announced a comprehensive restructuring plan designed to reduce its cost base, further right size its organization and optimize its global manufacturing infrastructure.

GVK BIO is pleased to announce the appointment of Dr. Robert (Bob) R. Ruffolo, to its Board of Directors.

AngioDynamics, Inc. announced financial results for the fourth quarter of fiscal year 2019, which ended May 31, 2019.

Moleculin Biotech, Inc. (Nasdaq: MBRX) (“Moleculin” or the “Company”), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors, today announced it has filed new patents covering the production and reconstitution of Annamycin, which is currently in two clinical trials for the treatment of relapsed or refractory acute myeloid leukemia (AML).

Kroger Health, the healthcare arm of The Kroger Co. providing health, wellness, and nutrition solutions to more than 14 million people nationwide, announced its partnership with Myriad Genetics to pilot Myriad Genetics’ GeneSight® pharmacogenomic test with Kroger Health Plan members.

DiscGenics, Inc., a clinical stage biotechnology company focused on developing regenerative cell-based therapies that alleviate pain and restore function in patients with degenerative diseases of the spine, today announced the first Utahns have been treated in its nationwide clinical study of IDCT, a locally developed injectable disc cell therapy for degenerative disc disease (DDD).

Hill-Rom Holdings, Inc. (NYSE: HRC), which recently rebranded as Hillrom, announced today that it has entered into a definitive agreement to sell certain surgical consumable products and related assets to an affiliate of Audax Private Equity (“Audax”) for $170 million in cash.

New microbroth dilution plates provide gold standard-level(1) minimum inhibitory concentration (MIC) accuracy using first- and second-line treatment options

Healthcare groups under one roof; poised for enhanced collaboration

The advantages of modified versions over conventional dosage forms are encouraging several companies to focus on developing modified versions of the existing corticosteroid preparations, and oral corticosteroids.